Neos Therapeutics to Host First Quarter 2017 Financial Results Conference Call on May 9, 2017
May 02 2017 - 07:30AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing, manufacturing and commercializing innovative
extended-release (XR) products using its proprietary
modified-release drug delivery and orally disintegrating tablet
(ODT) technology platforms, today announced that it will report its
first quarter 2017 financial results prior to the opening of U.S.
financial markets on Tuesday, May 9, 2017. Neos management will
host a conference call and live audio webcast to discuss these
results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877)
388-8985 for domestic calls, or +1 (562) 912-2654 for international
callers, and referencing conference ID number 94755525. A live
audio webcast for the conference call will be available on the
Investor Relations page of the company’s website at
http://investors.neostx.com/.
About Neos TherapeuticsNeos
Therapeutics, Inc. is a pharmaceutical company focused on
developing, manufacturing and commercializing products utilizing
its proprietary modified-release drug delivery technology
platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in
patients 6 years of age and older, is the first approved product
using the Company’s extended-release (XR)-orally disintegrating
tablet (ODT) technology platform. Neos, which is initially focusing
on the treatment of ADHD, has filed New Drug Applications with the
U.S. Food and Drug Administration for two other branded product
candidates that are XR medications in ODT or oral suspension dosage
forms. In addition, Neos manufactures and markets its generic
equivalent of the branded product Tussionex®, an XR oral suspension
of hydrocodone and chlorpheniramine indicated for the relief of
cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of
Companies.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Vice President
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2023 to Mar 2024